miltefosine + pentamidine

Miltefosine + pentamidine is a combination therapy used primarily for the treatment of leishmaniasis, a parasitic disease transmitted by sandflies. This combination has shown promising results in clinical trials, particularly for cutaneous and mucosal forms of the disease. ## Drug Information The combination consists of miltefosine, an oral medication, and pentamidine, which can be administered intralesionally or through inhalation depending on the type of leishmaniasis being treated. In clinical studies, this combination has demonstrated efficacy rates of up to 92% in treating Bolivian cutaneous leishmaniasis due to Leishmania braziliensis[1]. ### Mechanism of Action Miltefosine was originally developed as an anticancer agent in the 1990s before being repurposed for leishmaniasis treatment[4]. It's the only oral drug approved for leishmaniasis and works by interfering with cell signaling pathways and membrane synthesis in the parasite. Pentamidine acts by binding to DNA and disrupting the parasite's mitochondrial function. When combined, these drugs appear to have an additive effect, with miltefosine providing systemic protection against parasite dissemination while pentamidine delivers targeted treatment to the lesion area[1][6]. ### Clinical Applications The combination therapy has been studied in various forms of leishmaniasis: - **Cutaneous Leishmaniasis**: In a study of Bolivian cutaneous leishmaniasis, the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm² lesion area on days 1, 3, and 5) achieved a 92% cure rate[1]. - **Mucosal Leishmaniasis**: The combination of oral miltefosine and inhaled pentamidine has been investigated as a completely non-parenteral regimen that could lead to >90% cure of mild mucosal leishmaniasis[3]. ### Advantages of the Combination This combination offers several advantages over monotherapy: - Potentially additive efficacy compared to either drug alone - Avoidance of parenteral therapy (when using inhaled pentamidine) - Provides both local treatment and systemic protection - May reduce the length of treatment with miltefosine alone, potentially reducing costs and adverse events[6] ### Limitations The search results indicate that adverse effects and costs of the combination are additive[1]. Additionally, there have been challenges with miltefosine access, including supply chain inefficiencies and quality issues that have affected treatment outcomes in some regions[4]. ## Development Status The combination therapy has been studied in controlled clinical trials for cutaneous leishmaniasis caused by Leishmania braziliensis, with promising results suggesting it could be an effective treatment option, particularly in cases where high efficacy is a prime consideration or when parenteral therapy needs to be avoided[1][2].